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ABSTRACT: The position effect variegation in Drosophila and
Schizosaccharomyces pombe, and higher-order chromatin
structure regulation in yeast, is orchestrated by modifier genes of
the Su(var) group, (e.g., histone deacetylases ([HDACs]), protein
phosphatases) and enhancer E(Var) group (e.g., ATP [adenosine
5-triphosphate]-dependent nucleosome remodeling proteins).
Higher-order chromatin structure is regulated in part by covalent
modification of the N-terminal histone tails of chromatin, and
histone tails in turn serve as platforms for recruitment of
signaling modules that include nonhistone proteins such as
heterochromatin protein (HP1) and NuRD. Because the enzymes
governing chromatin structure through covalent modifications of
histones (acetylation, methylation, phosphorylation,
ubiquitination) can also target nonhistone substrates, a
mechanism is in place by which epigenetic regulatory processes
can affect the function of these alternate substrates. The
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posttranslational modification of histones, through
phosphorylation and acetylation at specific residues, alters
chromatin structure in an orchestrated manner in response to
specific signals and is considered the basis of a “histone code.” In
an analogous manner, specific residues within transcription
factors form a signaling module within the transcription factor to
determine genetic target specificity and cellular fate. The
architecture of these signaling cascades in transcription factors
(SCITs) are poorly understood. The regulation of estrogen
receptor (ER) by enzymes that convey epigenetic signals is
carefully orchestrated and is reviewed here.

EPIGENETICS

Epigenomics refers to the study of heritable changes in gene
expression that occur without a change in DNA sequence.
Through the silencing of tumor suppressor genes, epigenetic gene
regulation frequently plays a critical role in the pathogenesis of
cancer. Epigenomic modifications include covalent modifications
of DNA and histones as well as noncovalent changes regulating
nucleosome positioning. The enzymes regulating epigenetic
change have been characterized in a number of animal systems
including Drosophila and transgenic mice. Recent studies have
characterized the mammalian enzymes that regulate epigenetic
change. Environmental factors including hormones in turn
regulate activities of several enzymes, altering DNA methylation
and histone acetylation patterns.
Histone Methylation

Several recent studies have demonstrated the importance of
histone methylases and histone demethylases in regulating
estrogen receptor (ER) activity and expression. Posttranslational
modification that does not alter DNA sequence requiring
methylation occurs both on DNA and on proteins. Methylation of
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chromatin is often linked to methylation of DNA. A number of
histone methylating enzymes directly interact with DNA
methylating enzymes (DNA methytransferases (DNMTs) and
1
methyl-binding proteins). Modification by methylation of DNA
is generally targeted to cytosine residues in CpG dinucleotide
pairs. Methylation governs genomic stability, retroelement
suppression, and gene promoter regulation. Regions of CpG in
the mammalian genome include large CpG islands (>500 bp),
small CpG islands (200–500 bp) associated with transposons, and
nonisland CpGs. DNA methyltransferases are associated with the
replication complex in mammalian cells. This finding is
consistent with a model in which the signals for methylating
sequences in the genome are provided by a pre-existing
hemimethylation. Thus, replication of the sequence to daughter
chromatids temporarily results in hemimethylated DNA, which is
recognized by DNMTs, ensures restoration of the symmetrical
methylation of both DNA strands. The other major signal for
methylation in mammalian cells is the presence of SINE
36
elements.
Methylation of histones occurs on either lysine or alanine
residues, resulting in either condensation or relaxation of the
chromatin architecture. Methylation likely provides binding sites
for regulatory proteins with specialized binding domains. The
main sites of methylation of histones occur on either
heterochromatin or euchromatin. Heterochromatin is condensed
and considered transcriptionally silent, whereas euchromatin is
less densely packed and transcriptionally active. Methylated
lysine residues are located characteristically within
1
heterochromatin and demarcate subdomains. Methylated histone
residues serve as docking sites for repressive proteins, including
the polycomb protein (PC) and heterochromatin protein (HP1),
which recognize histone H3, K27 or H3, K9, respectively. HP1
and PC recognize methylated lysine residues through their
chromo domain. Other proteins recognize methylated lysine
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residues though two other motifs, known as the Tudor domain
and the WD40 repeat domain.
Histone methylation by protein arginine methyltransferases
represents a relatively prevalent modification of proteins. The
protein arginine methyl transferases (PRMTs) consist of two
types, differing in the asymmetry of the dimethylarginine,
product. The Type 1 PRMT forms monomethylarginine and
asymmetric dimethylarginine, whereas Type 2 PRMT forms
monomethylarginine and symmetric dimethylarginine. The
PRMTs, 1, 2, 3, 4, and 6 are Type 1 PRMTs. The Type 2 PRMT
is represented by PRMT5, also known as CARM1 (coactivator4
associated arginine methyltransferase). Stallcup and coworkers
demonstrated that CARM1 encodes both an arginine
methyltransferase and a nuclear receptor coactivator, linking
posttranslational modification by methylation to ER receptor
signaling.
The histone lysine methylases share a common SET (Su/var,
Enhancer of Zeste, Trithorax) domain. The SET domain conveys
the S-adenosyl-Lmethionine cofactor to the epsilon amino group
of the lysine residues. The histone H3 lysine 9 methyltransferase
group catalyzes H3, lysine 9 methylation and includes Suv39h1,
Suv39 h2, G9a, G9a-related protein and the SET DB1 gene
products.
Enzymatic demethylation of histone was first described in 1973
37
by Paik and Kim. The identification of specific proteins
regulating this activity took many years to be identified, however.
Recently several lysine specific demethylases have been
described, including lysine specific demethylase 1 (LSD1),
32
JHDM1, JHDM2A, and JMJD2.
In addition to removal of arginine methylation by lysine
demethylases, the methyl group can be removed from the
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arginine by the conversion of the methylarginine residue into
citrulline, referred to as deimination. Deimination is conducted
by arginine peptidyl arginine deiminase 4 (PADI4), which
converts unmodified arginine and monomethylated arginine to
6
citrulline at specific sites on the tails of H3 and H4. Importantly,
for the purpose of this review, PADI4 repressed the estrogenregulated gene, pS2, linking arginine demethylation to ER
signaling.
Histone Acetyltransferases and Deacetylases
ER function can be regulated by histone acetylases and histone
deacetylases (HDACs). Euchromatic DNA is packaged by
histones into nucleosomes composed of 147 base pairs of DNA
and the core histone proteins (H2A, H2B, H3, and H4). Dramatic
alterations in chromatin structure are modulated through
9
posttranslational modification of lysine tails. Conserved lysine
residues are present in the amino terminal tails of all four core
histones. Acetylation of lysine residues is thought to both
neutralize the basic charge of histone tails and to serve as
epigenetic markers which provide recognition motifs for docking
of proteins that recruit transcriptional activators or repressors.
The histone acetyl-transferase (HAT) enzymes were historically
described as Type A, located in the nucleus, and Type B, located
in the cytoplasm. Type B typically have a housekeeping role,
acetylating newly synthesized free histones, whereas Type A
HAT acetylate nucleosomal histones within chromatin in the
nucleus. The Type A nuclear HATs include five families, the
Gcn5-related acetyltransferases (GNATs), the MYST (MOZ,
Ybf2/Sas3, Sas2, and Tip60)-related HATs, the HATs regulating
general transcription (TAFII250), the CBP/p300 cointegrator
9
HATs; and the p160 coactivator HATs, (SRC-1 and SRC3).
The dynamic remodeling of acetylated lysine residues is
mediated through two distinct types of HDACs: trichostatin A
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(TSA)-sensitive and NAD-regulated. TSA-sensitive HDACs
include the class 1 HDACs (HDACs 1, 2, 3, and 8) which are
related to the Saccharomyces cerevisiae transcriptional regulator
RPD3. The class II HDACs are related to the yeast HDA1 protein
and include HDACs 4, 5, 6, 7, 9, and 10. HDAC 11 is more
related to the Type 1 HDACs and contains a catalytic domain at
the N-terminus with HDAC activity.
NUCLEAR RECEPTORS
Nuclear receptors function as transcription factors that govern
transcription of genes. Their activity can be regulated by steroids,
thyroid hormone, retinoic acids, or vitamins, and they coordinate
diverse processes such as homeostasis, reproduction,
40
development, metabolism, and disease. There are four main
conserved domains of all nuclear receptors. These domains
include the activation function domain (AF), the DNA-binding
domain (DBD), the hinge region, and the ligand-binding domain
(LBD), the latter being the site of many protein–protein and
hormone interactions.
Coregulator proteins, both coactivators and corepressors, work
with nuclear receptors in complexes that govern gene expression.
Nuclear receptors and the transcriptional apparatus are often
linked together through coactivator recruitment of protein
complexes. These complexes then can use their histonemodifying abilities to alter the local chromatin structure. Several
coactivators that bind to nuclear receptors include steroid
receptor coactivator-1 (SRC-1), amplified in breast
cancer1/thyroid and RA receptor/SRC-2 (AIB1/ACTR/SRC-2),
glucocorticoid receptor interacting protein 1/transcriptional
intermediary factor 2/SRC-3 (GRIP1/TIF-2/SRC3), menin, and
17,18,51
p300/CBP and p300/CBP-associated factor (p/CAF).
Corepressors function with unliganded nuclear receptors to
silence gene expression. These corepressors include proteins like
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nuclear receptor corepressor (N-CoR), silencing mediator of
retinoid and thyroid hormone receptor (SMRT), Sin3, HDACs,
thyroid hormone receptor uncoupling protein (TRUP), BRCA1,
17,18,51
NuRD, Suv39h1, DNMT1, pRB2/p130, and E2F4/5.

THE ESTROGEN RECEPTOR
The last two decades have seen an evolving body of literature
providing a compelling case for dynamic regulation of ER
function through both posttranslational modification by
acetylation and through epigenetic signaling cascades. The
nuclear receptor, ER, is activated by, and controls the activity of,
the steroid hormone, estrogen. Together estrogen and its receptor
are vitally important in normal development, reproduction, and
various diseases. ER is distributed at the cellular membrane, the
cytoplasm, the nucleus, and the mitochondria. The membranebound form of ER regulates nongenomic function through
interactions with SHC and caveolin-1, inducing acute activation
of PI3 kinase and Akt signaling pathway. The nuclear form
provides DNA-dependent regulation of gene expression.
Epigenetic regulation has been well characterized for the nuclear
located ER. The role of epigenetic signals of ER located in other
compartments of the cell remains to be better understood.
ER binds DNA either directly or through other transcription
factors (AP-1, Sp1) in order to regulate transcription of target
genes. The ER functional activity in the nucleus is mediated
through binding of coactivator and corepressors, which encode
enzymes with HAT-modulating activity. The cointegrators
CBP/p300 (CREB-binding factor) encode intrinsic HAT activity.
The binding of HATs to the ER provides a docking function
leading to acetylation of local histones with consequent
nucleosomal destabilization facilitating transcription factor
binding to local DNA sequences at promoter regions of estrogen______________________________
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responsive genes. Some proteins that are already known to bind
the ER include members of the p160 family (SRC-1,
TIF2/GRIP1/SRC-2, AIB1/ACTR/SRC-3), cyclin D1, menin,
21,29,30
and many HATs (CBP, p300, p/CAF).
The p160 coactivator
family (SRC1/amplified in breast cancer/activator of the thyroid
and RA receptor/ SRC-2 to [AIB1/ACTR/SRC3]) and the related
group 1 (GRIP-1/TIP-2/SRC-2) facilitate the interaction between
the p300 coactivator and the nuclear receptor. In addition, nuclear
receptor repressors of the N-CoR and SMRT complex physically
associate with the ER particularly in the presence of the ER
ligand antagonists such as tamoxifen. The ER has been shown to
physically associate with several corepressors which encode
8
intrinsic HDAC activities including BRCA1 and MTA1. BRCA1
binds the ER to repress ligand-induced gene expression. BRCA1
repression of ER is opposed by endogenous cyclin D1 through
45
physical association within local chromatin (FIG. 1). It is
plausible that BRCA1 association with ER may play a role in the
recently described finding that transient double-stranded DNA
break formation occurs during ER ligand-dependent gene
24
transcription.
Epigenetic Modifiers Silence the ER Gene
In breast cancer ER gene expression is an important prognostic
52
factor. Altered expression and function of ER coregulators with
epigenetic function have been demonstrated to play a role in
hormone signaling. The AIB1 protein is frequently amplified in
2
breast cancer correlating with the ER-positive status. The
expression levels of TIP2, CBP, and ER are strongly correlated in
31
intraductal breast carcinomas. Furthermore, tamoxifen-resistant
tumors show a shorter relapse of survival in samples with low
20
expression of NCoR.
Unfortunately though, 30% of breast cancers are ER-negative
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22

upon diagnosis and many breast cancers can lose ER expression
during progression of the cancer. In many patients epigenetic
modification plays a role in the loss of ER gene expression. Yang
54
et al. demonstrate reduced ER expression due to increased DNA
54
methylation and/or histone deacetylation. The demethylase
PADI4 has been linked to the repression of the estrogen6
responsive gene pS2. HDACs bind ER and HDAC
25
overexpression silences expression of the ER gene. siRNA39,53
mediated reduction of DNMT1 induced ER expression.
Two
commonly used inhibitors of this silencing mechanism are the
DNMT inhibitor, 5-aza-2-deoxycytidine (5-aza-dC), and the
HDAC inhibitor, TSA. Treatment with either inhibitor
25,54,55
individually enhanced ER gene expression.
Use of both 5aza-dC and TSA enhanced re-expression of both ER mRNA and
protein in human breast cancer cells. The re-expressed ER was
functional and it induced expression of known ER target genes.
Collectively these studies suggest how inhibitors of HDACs and
DNMTs may be used to reinduce ER expression and thereby
restore therapeutic response to ER antagonists.
34

Macaluso et al. examined further the mechanisms silencing
the ER gene and identified several multimolecular ER repression
complexes. pRb2/p130E2F4/5-HDAC1-SUV39H1-p300 or
pRB2/p130-E3F4/5-HDAC1-DNMT1SUV39H1 proteins were
found on the ER promoter. These complexes included HDACs,
DNMTs, the histone methyltransferase, SUV39H1, and the cell
cycle regulatory protein, pRb2/p130. It was hypothesized that
protein complexes recruited by pRb2/p130 modulate acetylation
or methylation to the ER promoter, regulating its expression by
altering the local chromatin structure through the histone
42
methyltransferases, like SUV39H1. Sharma et al. examined the
multimolecular protein complexes upon treatment of cells with 5aza-dC and TSA. Cells with silenced ER demonstrated DNA
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hypermethylation, histone hypoacetylation, H3K9 methylation,
and an increased abundance of methyl-binding proteins, DNMTs,
and HDACs. Treatment of these cells with the HDAC and
DNMT inhibitors led to ER re-expression, release of the
repressor complexes, enrichment of histone acetylation, and
decreased H3K9 methylation.

The ER Works in Regulating Target Gene Transcription with
Coregulators
In addition to the HATs and HDAC-containing complexes, ER
forms protein complexes with other coregulatory proteins to
govern expression of genes.
A component of a histone methyltransferase complex regulates
7
the ER to further regulate target genes. Menin is the protein
product of the multiple endocrine neoplasia 1 (MEN1) tumor
suppressor gene. It is a component of the MLL1/MLL2 H3K4
histone methyltransferase complex, which is typically linked to
gene activation. Menin physically associates with the ER and
works as a coactivator to activate the expression of the ER target
7
gene, pS2 (TFF1). Importantly, MEN1 mutations associated with
disease disrupted any ER-menin interaction and the ER activity.

Acetylation of the ER Regulates its Activity
In the first studies demonstrating direct acetylation, the ER was
shown to be acetylated in MCF7 human breast cancer cells by
44
immunoprecipitation Western blotting. GST-fusion proteins of
the ER were then shown to serve as in vitro substrates for
acetylation in the presence of p300, produced in baculovirus.
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Deletion analysis identified a minimal region of ER acetylated by
p300. Edman degradation assays and MALDI-TOF mass
spectrometry identified the acetylated residues as preferentially
lysine K302 and K303 with some minimal acetylation of lysine
299. A minimal ER peptide was acetylated by p300 with similar
efficiency as histone H3. Point mutations of the lysine residues in
ER resulted in ER mutants that were activated at lower
concentrations of E2 than the wild-type ER. Glutamine or alanine
substitutions of the acetylated lysine residues enhanced
transactivation; in particular, ER activation by p300 was
enhanced. The alteration in transactivation by the acetylation site
was distinct and did not affect activation by other kinases,
including mitogen-activated protein kinase or activation by the
44
p68 RNA helicase A. The ER K303R mutation conferred
enhanced activation of ER activity at low subphysiological levels
of hormone. The ER lysine motif that was acetylated directly by
p300 was shown to be conserved across species and the motif
was identified in many other phylogenetically related receptors,
44
including the androgen receptor and PPAR (FIG. 2). Analysis of
the related lysine motif in the AR demonstrated a similar
11,14–16
biochemical function and growth-regulatory properties.
Independently of these findings another laboratory had
identified a point mutation of the ER at K303 occurring as a
19
somatic mutation in human breast cancer. The mutation of
K303 occurred with high frequency (30%) of early breast cancer
lesions, referred to as ductal carcinoma in situ. The ERK303R
mutant conveyed a growth advantage to breast carcinoma cells in
19
culture. Growth assays demonstrated that the acetylation site
ERK303R mutation enhanced cellular proliferation in response to
low concentrations of estradiol, suggesting the ER K303R
mutation provides a “gain of function” mutation in human breast
cancer.
Analysis of other nonhistone substrates for acetylation, such as
______________________________
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p53, provides evidence that the acetylation of transcription
28
factors may in turn regulate their phosphorylation by distinct
28
kinases. Thus, acetylation of lysine 320 prevents
phosphorylation of serine in the NH2-terminal region of p53. The
ER is phosphorylated by protein kinase A at residue 305. The
generation of a kinase-active mutant of the ER through the
introduction of an aspartic acid residue blocked acetylation of the
5
ER. Studies by Cui et al. demonstrating ER acetylation is linked
to phosphorylation of the ER at residue serine 305 may be of
importance to therapy resistance in breast cancer, as PKA
35
activation of ER has been linked to tamoxifen resistance. These
studies suggesting that acetylation and phosphorylation within
the ER are coupled are consistent with prior studies coupling
11,50
acetylation and phosporylation of the androgen receptor.
p53 is known to be acetylated at distinct sites coordinating
28
distinct signaling pathways. It is known that p300/CBP
acetylates carboxyl-terminal lysine residues of p53 (lysines 372,
373, 382). P/CAF acetylates a residue within the flexible linker
region of p53 (lysine 320). In response to genotoxic stress, DNA
damage induces acetylation of lysine 320 and lysine 373 with
distinguishable kinetics. These two distinct acetylation sites
regulate distinct clusters of genes with high-affinity p53-binding
28
sites, promoting cell survival. In contrast K373 regulates
interactions with affinity DNA-binding sites found in
proapoptotic genes leading to cell death. In keeping with the
finding of multiple modular acetylation sites in p53, additional
acetylation sites were identified in the ER at lysine K266 and
27
K268. Contrary to K302/303, which were acetylated directly by
44
p300, K266/268 was acetylated in an assay using p300/p160
(SRC1) and the ligand estradiol.
Although the distinguishable biological functions of the ER
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lysine residues remains to be determined, the acetylated residues
in the androgen receptor (K302/303) promote DNA synthesis and
11,14–16
antiapoptotic signals.
The AR acetylated residues regulate
11
access to DNA in chromatin immune precipitation assays and
promote binding to promoters of target genes that induce DNA
11,14–16
synthesis such as cyclin D1.
The p53 acetylation site also
alters access within the local chromatin structure to enhance
28
DNA binding. In electrophoretic mobility shift assays, the ER
acetylation (K266, and K268) was shown to regulate DNA
binding, whereas acetylation of the ERK303 site does not affect
binding. The application of an unbiased proteomic approach to
examine ER residues acetylated in vivo under physiological
conditions and in tumors will be of interest (FIG. 3).
Cyclin D1 Regulates ER Activity
The cyclin D1 gene product is overexpressed in 30–40% of
cancers and is associated with poor prognosis in ER-positive
26,38
breast cancer patients.
Initially cloned as part of a breakpoint
rearrangement in parathyroid adenoma, the cyclin D1 protein has
subsequently been shown to bind HDACs, the pRB protein, and
13
several transcription factors. Cyclin D1 contributes a catalytic
subunit function of a kinase that phosphorylates pRb and
41,47
NRF1.
Phosphorylation of pRB in the nucleus regulates DNA
synthesis, while phosphorylation of NRF1 regulates
41,47
mitochondrial biosynthesis.
At the membrane, cyclin D1
promotes cellular migration, and angiogenesis through induction
of cytokines and vascular growth regulatory proteins (VEGF,
33
TSP1).
The role of cyclin D1 in regulating the nuclear receptor is
complex. In vivo, cyclin D1 knockout mice develop a phenotype
of enhanced PPAR activity with hepatic steatosis due to the
______________________________
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48

inhibition of PPAR activity by cyclin D1. Cyclin D1 has been
shown to associate with the ER and enhance ER activity, in part
through recruiting the SRC1 p160 coactivator in a ligand56
independent manner, and also through antagonizing the ER
43
corepressor BRCA1. Cyclin D1 functions in regulating both ER
and BRCA1 occupancy in the context of local chromatin at an
43
estrogen response element of the pS2 gene. The finding that
cyclin D1 regulates local chromatin occupancy is consistent with
the findings that cyclin D1 binds SUV39, HP1 and HDACs and
that the abundance of cyclin D1 determines the local acetylation
10,23,46
of histones, including histone H3 Lys9.
It is known that
mammary-targeted expression of cyclin D1 induces mammary
tumorigenesis in transgenic mice. Therefore, it will be of interest
to determine the relative importance of these kinase-independent
functions of cyclin D1 in inducing mammary tumorigenesis and
estrogen responsiveness.
CONCLUSIONS
Over the last decade histone-modifying enzymes have been
successfully cloned and characterized. These posttranslational
modifications within histone tails provide the basis of signaling
modules within the local chromatin, known as the “histone code.”
Recent studies have demonstrated the presence of similar enzyme
complexes associated with the ER. Similar to histone tails,
transcription factors, such as p53 and the nuclear receptors,
ERand the AR, encode signaling modules within the protein, in
which one posttranslational modification leads to a sequential
commitment to other types of posttranslational modifications.
Cascades of acetylation, phosphorylation, and ubiquitination
modify the receptors’ function, genetic response, and consequent
cell fate decisions. Although these signaling cascades in
transcription factor or SCITs are poorly understood at this time,
the residues for posttranslational modification appear to be well
conserved across species. In the same manner that cytoplasmic
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signaling cascades in the last decades defined kinase modules, so
too will the next decade provide important insights into
intratranscription factor signaling cascades that may ultimately
contribute to the biological specificity of nuclear receptor
signaling.
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FIGURES

FIGURE 1. Hypothetical model by which cyclin D1 augments
8
ER signaling. The ER activity is repressed by BRCA1,
Endogenous cyclin D1 opposes the action of BRCA1 at an
ERE. Cyclin D1 associates directly with the ER The prevailing
view in cancer biology is that two general classes of cancer
genes exist, those that regulate genomic stability including
antimutators and DNA repair genes, and a second class of
genes regulating cell cycle control. Cyclin D1 shares both
properties, promoting DNA synthesis and regulating the
43
function of BRCA1. Estradiol induces BRCA1 to the pS2
43
ERE in ChIP assays, an effect antagonized by cyclin D1, and
E2 induces transient double-strand breaks with the recruitment
of DNA repair complexes to the ERE of the pS2 gene.
Collectively these studies support a model in which cyclin D1
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regulates both cell proliferation and DNA repair function.

FIGURE 2. Phylogenetic conservation of the acetylation
motif. The phylogenetic tree linking nuclear receptors in
vertebrate arthropods and nematodes is shown. Nuclear receptors
containing the acetylation motif are shown in yellow, whereas
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nuclear receptors lacking the motif are shown in pink.

FIGURE 3. The ER is regulated by TSA and NAD-dependent
HDACs. The ER and the AR are acetylated at conserved lysine
residues. Although NAD regulates ER activity, p300, an essential
3
coactivator of ER, is also repressed by Sirt1. The AR has been
shown to be directly regulated by acetylation in response to
physiological stimuli and to be repressed by SIRT1 in a catalytic
12
domain-dependent manner. An acetylated AR substrate
functions as an excellent substrate for SIRT1. The nuclear
receptor acetylation site governs nuclear receptor function, as
indicated to the right, including transactivation DNA synthesis
and apoptosis. In the case of the AR, the transrepression and
sumoylation of the AR are unaffected by acetylation.
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